1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline profile

1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline is a synthetic compound that has gained attention in research for its potential pharmacological properties. It is closely related to the naturally occurring alkaloid **salutaridine**, which is found in the opium poppy and is a precursor to morphine.

Here's what makes it interesting for research:

**1. Potential as an opioid analgesic:**

* Like salutaridine, 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline exhibits opioid-like activity, meaning it binds to opioid receptors in the brain and can potentially relieve pain.
* Research is investigating whether this compound could be a safer and less addictive alternative to morphine.

**2. Antidepressant activity:**

* Studies suggest that this compound may possess antidepressant properties.
* This activity is attributed to its potential to modulate neurotransmitter systems involved in mood regulation, such as dopamine and serotonin.

**3. Anti-inflammatory effects:**

* Preliminary research indicates that 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline may have anti-inflammatory properties.
* This aspect is particularly interesting for its potential applications in treating inflammatory conditions.

**4. Neuroprotective properties:**

* There's ongoing research to explore whether this compound could protect neurons from damage caused by various factors, such as oxidative stress and neurotoxins.

**5. Investigational drug development:**

* The unique pharmacological profile of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline has sparked interest in developing it as a potential drug for treating a range of medical conditions.

**Important note:**

While research is promising, it's crucial to understand that this compound is still in the early stages of investigation. Further research is needed to determine its safety, efficacy, and optimal therapeutic applications before it can be considered for human use.

1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline: present in Parkinsonian & normal brains; RN refers to (S)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	124148
CHEBI ID	88540
MeSH ID	M0188937

Synonym
(s)-n-methylsalsolinol
53622-85-8
1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1,2-dimethyl-, (s)-
1,2-ddtiq
DTXSID90201867
(1s)-1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
n-methylsalsolinol
CHEBI:88540
n-methyl-(s)-salsolinol
Q27160431
(s)-1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol

Excerpt	Reference	Relevance
" In general, catechol isoquinolines were more toxic than isoquinolines without catechol structure."	( Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblastoma SH-SY5Y cells. Deng, Y; Dostert, P; Maruyama, W; Nakahara, D; Naoi, M; Niwa, T; Ohta, S; Takahashi, T, 1997)	0.3

Class	Description
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (66.67)	18.2507
2000's	1 (16.67)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	1.97	1	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.04	1	primary amine
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	1.99	1	xanthene
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	1.99	1	phenoxazine
2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline: present in parkinsonian & normal human brains; RN given refers to parent cpd; structure given in first source	6.97	1	isoquinolinol; tertiary amino compound	human metabolite; neurotoxin; rat metabolite
salsoline salsoline: monomethylated metabolite of salsolinol; endogenous neurotoxin found in CSF of patients with Parkinson's disease	1.99	1	isoquinolines
salsolinol salsolinol: RN given refers to cpd without isomeric designation; EP to SALSOLINE ALKALOIDS (78-82); on-line search SALSOLINE ALKALOIDS (78-82); Index Medicus search ISOQUINOLINES (78-82). (S)-salsolinol : A 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol that has S-configuration.	1.99	1	1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol	human urinary metabolite

Condition	Relationship Strength	Studies
Drug Withdrawal Symptoms [description not available]	2.04	1
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	2.04	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.99	1
Atherosclerotic Parkinsonism [description not available]	1.99	1
Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)	1.99	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	1.99	1
Idiopathic Parkinson Disease [description not available]	1.97	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	1.97	1

1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline

Description

Cross-References

Synonyms (12)

Research Excerpts

Toxicity

Drug Classes (1)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.43

Study Types